Lymphoma clinical trials in Montana

10 actively recruiting lymphoma trials at 9 sites across Montana.

Data from ClinicalTrials.gov · last refreshed 2026-07-07

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

BeOne Medicines funds and runs this clinical trial (NCT05100862). In 2024, BeOne Medicines and 1 other company reported paying the doctors leading the trial a total of $4,827,812 for research work on this study.

Who paid

BeiGene, Ltd. $4,687,730
BeiGene USA, Inc. $140,082

Paid for research work on this trial

CHIJIOKE NZE $460,483
PORNCHAI JONGLERTHAM(oncologist on CancerDrs) $402,494
STEVEN MCCUNE(oncologist on CancerDrs) $379,879
BEI HU(oncologist on CancerDrs) $332,245
DAVID BERZ(oncologist on CancerDrs) $292,543

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Research payments are not, by themselves, a conflict — paying for legitimate trial work is how drug development gets funded. The purpose of Sunshine Act disclosure is to give patients the context, not to make the decision for them.

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

Loxo Oncology, Inc. funds and runs this clinical trial (NCT05254743). In 2024, Loxo Oncology, Inc. reported paying the doctors leading the trial a total of $2,037,139 for research work on this study.

Who paid

Eli Lilly and Company $2,037,139

Paid for research work on this trial

RICHY AGAJANIAN(oncologist on CancerDrs) $243,858
SALEHA SAJID(oncologist on CancerDrs) $165,169
CHANH HUYNH(oncologist on CancerDrs) $153,966
BRUCE CHESON(oncologist on CancerDrs) $152,368
JENNIFER CULTRERA(oncologist on CancerDrs) $151,740

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Phase 3 Recruiting Academic/Other

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT03150693

Sites in Montana:

Community Hospital of Anaconda — Anaconda, Montana
Billings Clinic Cancer Center — Billings, Montana
Saint Vincent Healthcare — Billings, Montana
Saint Vincent Frontier Cancer Center — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05976763

Sites in Montana:

Community Hospital of Anaconda — Anaconda, Montana
Billings Clinic Cancer Center — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana
Benefis Sletten Cancer Institute — Great Falls, Montana
Logan Health Medical Center — Kalispell, Montana

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. U…

Sponsor: Eastern Cooperative Oncology Group

NCT ID: NCT06724237

Sites in Montana:

Saint Patrick Hospital - Community Hospital — Missoula, Montana

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free surviv…

Sponsor: BeOne Medicines

NCT ID: NCT05100862

Sites in Montana:

St Vincent Frontier Cancer Center — Billings, Montana

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT06136559

Sites in Montana:

Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0052) — Billings, Montana

View on ClinicalTrials.gov →

Phase 2, Phase 3 Recruiting Industry

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of…

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT05139017

Sites in Montana:

St. Vincent Frontier Cancer Center-Research ( Site 0108) — Billings, Montana

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …

Sponsor: Loxo Oncology, Inc.

NCT ID: NCT05254743

Sites in Montana:

St. Vincent Frontier Cancer Center — Billings, Montana

View on ClinicalTrials.gov →

Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05334069

Sites in Montana:

Community Hospital of Anaconda — Anaconda, Montana
Billings Clinic Cancer Center — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana
Benefis Sletten Cancer Institute — Great Falls, Montana
Great Falls Clinic — Great Falls, Montana

View on ClinicalTrials.gov →

Recruiting Network

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer …

Sponsor: ECOG-ACRIN Cancer Research Group

NCT ID: NCT06002828

Sites in Montana:

Saint Patrick Hospital - Community Hospital — Missoula, Montana

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in Montana:

Massive Bio SYNERGY-AI site — Billings, Montana

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07